All studies
CompletedPhase IInterventional

A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosis

Multiple myeloma and AL amyloidosis are rare blood conditions caused by abnormal plasma cells, a type of white blood cell. While existing treatments can control them for a time, these conditions often return or become resistant to treatment. This clinical trial is testing a new drug called JNJ-79635322. Because this is a Phase 1 trial, it is the first time this medicine is being given to people. The main goals are to check its safety, find the best and safest dose, and watch for any side effects. Doctors will also measure how the drug affects the cancer cells. The study involves regular hospital visits for treatment, blood tests, and scans. Taking part is entirely voluntary, and participants can choose to leave the study at any time.

At a glance

Status
Completed
Phase
Phase I
Sponsor
Janssen Research & Development, LLC
Enrolment target
180
Start
22 Nov 2022
Estimated completion
28 Aug 2025

What is this study about?

Multiple myeloma is a type of bone marrow cancer that affects plasma cells, which normally help fight infections. AL amyloidosis is a closely related condition where abnormal plasma cells produce faulty proteins that build up in organs. While modern treatments help many people manage these diseases, both conditions can return (relapse) or stop responding to standard medicines (refractory). When this happens, doctors need new treatment options.

This trial is testing an experimental medicine called JNJ-79635322. It is designed to help the body's immune system recognise and attack abnormal plasma cells. Because this medicine has not been tested in humans before, researchers need to find out how safe it is and how the body handles it.

The trial is split into two parts. In the first part, small groups of participants receive slowly increasing doses so doctors can discover the safest amount to give. In the second part, more patients will receive this chosen dose to learn more about how well it works. The findings will help doctors decide whether this medicine should be tested in larger clinical trials in the future.

Key takeaways

  • Tests a brand-new medicine, JNJ-79635322, for multiple myeloma and AL amyloidosis.
  • A Phase 1 trial focused on finding a safe and effective dose.
  • Aimed at adults whose disease has returned or not responded to earlier therapies.
  • Requires regular clinic visits for treatment, blood tests, and health checks.
  • Participation is entirely voluntary and you can withdraw at any time.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with either multiple myeloma or AL amyloidosis. To take part, your illness must have returned or stopped responding after you have already tried standard treatments.

For people with multiple myeloma, this usually means you have already received several standard medicines, including common drug classes such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapies. For people with AL amyloidosis, you must have tried standard therapies and have no other proven options left.

You will also need to be reasonably active and able to look after yourself in daily life (an ECOG score of 0 or 1). Your doctor will need to confirm that your illness can be measured through routine blood, urine, or imaging tests so they can track your progress.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with multiple myeloma or AL amyloidosis.
  3. My condition has returned or stopped responding after standard treatments.
  4. I am well enough to walk and carry out light daily activities.
  5. I am willing to attend regular hospital appointments and tests.
Answer every question to see your result.

What does participation involve?

Taking part begins with a screening period lasting up to 28 days to make sure the trial is safe for you. If you join, you will receive JNJ-79635322 as a hospital treatment. The study has two phases: Part 1 tests different dose levels to find the safest dose, and Part 2 gives that chosen dose to a larger group. You will stay on the treatment for as long as it keeps helping you and does not cause unacceptable side effects. Throughout the trial, you will attend regular hospital visits for health checks, blood tests, urine tests, scans, and occasional bone marrow tests. After your treatment finishes, the medical team will monitor your health for around 16 weeks.

Potential risks and benefits

Because JNJ-79635322 is a new medicine, researchers do not yet know if it will improve your condition. Potential side effects are still being learned, but they may include immune reactions, low blood cell counts, and a higher risk of infections. The study team will monitor you very closely to manage any symptoms quickly. Taking part may not directly cure your illness, but it could help doctors develop new therapies for others in the future. You are free to leave the trial at any point without it affecting your standard NHS care.

Locations (16)

  • Royal Marsden Hospital
    Approximate
    Sutton, Surrey, England
  • University College Hospital
    Approximate
    London, England
  • Ghent University Hospital
    Approximate
    Gent, Belgium
  • University Hospital of Liège
    City only
    Liege, Belgium
  • Antwerp University Hospital
    City only
    Edegem, Belgium
  • Centre hospitalier universitaire de Nantes
    Unverified
    Nantes, France
  • Lyon Sud Hospital Center
    Unverified
    Pierre benite, France
  • Institut Claudius Regaud Toulouse
    Unverified
    Toulouse, Occitanie, France
  • CHU de Rennes - Hôpital Pontchaillou
    Unverified
    Rennes, Bretagne, France
  • VU University Medical Center
    Unverified
    Amsterdam, Netherlands
  • University Medical Center Utrecht
    Unverified
    Utrecht, UT, Netherlands
  • Hospital Universitario Fundación Jiménez Díaz
    Unverified
    Madrid, Spain

Common questions

What does 'first-in-human' mean?

It means this is the very first time the medicine is being tested in people after being developed in laboratory research.

Will I definitely receive the study drug?

Yes. This is an open-label study without a dummy drug (placebo), so every participant receives JNJ-79635322.

How often will I need to visit the hospital?

Visits will be frequent, especially at the start, to give you the medicine and monitor your health closely. Your trial team will give you a full schedule.

Can I leave the study if I change my mind?

Yes. You have the right to withdraw from the trial at any time, for any reason, and your normal medical care will continue.

Does taking part cost anything?

The trial medication and study-related tests are provided free of charge, and travel expenses are often reimbursed. Check details with the study team.

How to find out more

Louis Bornman

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.